Suppr超能文献

SHOX基因单倍剂量不足作为综合征性和非综合征性身材矮小的一个病因

SHOX Haploinsufficiency as a Cause of Syndromic and Nonsyndromic Short Stature.

作者信息

Fukami Maki, Seki Atsuhito, Ogata Tsutomu

机构信息

Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Hamamatsu, Japan.

Department of Orthopedic Surgery, National Center for Child Health and Development, Tokyo, Japan.

出版信息

Mol Syndromol. 2016 Apr;7(1):3-11. doi: 10.1159/000444596. Epub 2016 Mar 15.

Abstract

SHOX in the short arm pseudoautosomal region (PAR1) of sex chromosomes is one of the major growth genes in humans. SHOX haploinsufficiency results in idiopathic short stature and Léri-Weill dyschondrosteosis and is associated with the short stature of patients with Turner syndrome. The SHOX protein likely controls chondrocyte apoptosis by regulating multiple target genes including BNP,Fgfr3, Agc1, and Ctgf. SHOX haploinsufficiency frequently results from deletions and duplications in PAR1 involving SHOX exons and/or the cis-acting enhancers, while exonic point mutations account for a small percentage of cases. The clinical severity of SHOX haploinsufficiency reflects hormonal conditions rather than mutation types. Growth hormone treatment seems to be beneficial for cases with SHOX haploinsufficiency, although the long-term outcomes of this therapy require confirmation. Future challenges in SHOX research include elucidating its precise function in the developing limbs, identifying additional cis-acting enhancers, and determining optimal therapeutic strategies for patients.

摘要

位于性染色体短臂假常染色体区域(PAR1)的SHOX基因是人类主要的生长基因之一。SHOX单倍剂量不足会导致特发性身材矮小和Léri-Weill软骨发育不全,并与特纳综合征患者的身材矮小有关。SHOX蛋白可能通过调控包括BNP、Fgfr3、Agc1和Ctgf在内的多个靶基因来控制软骨细胞凋亡。SHOX单倍剂量不足通常是由PAR1中涉及SHOX外显子和/或顺式作用增强子的缺失和重复引起的,而外显子点突变占病例的比例较小。SHOX单倍剂量不足的临床严重程度反映的是激素状况而非突变类型。生长激素治疗似乎对SHOX单倍剂量不足的病例有益,尽管该疗法的长期效果尚需证实。SHOX研究未来面临的挑战包括阐明其在四肢发育中的精确功能、识别其他顺式作用增强子以及确定针对患者的最佳治疗策略。

相似文献

1
SHOX Haploinsufficiency as a Cause of Syndromic and Nonsyndromic Short Stature.
Mol Syndromol. 2016 Apr;7(1):3-11. doi: 10.1159/000444596. Epub 2016 Mar 15.
2
5
A Leri-Weill dyschondrosteosis patient confirmed by mutation analysis of SHOX gene.
Ann Pediatr Endocrinol Metab. 2015 Sep;20(3):162-5. doi: 10.6065/apem.2015.20.3.162. Epub 2015 Sep 30.
7
[Short stature caused by SHOX gene haploinsufficiency: from diagnosis to treatment].
Arq Bras Endocrinol Metabol. 2008 Jul;52(5):765-73. doi: 10.1590/s0004-27302008000500008.
8
Clinical and molecular evaluation of SHOX/PAR1 duplications in Leri-Weill dyschondrosteosis (LWD) and idiopathic short stature (ISS).
J Clin Endocrinol Metab. 2011 Feb;96(2):E404-12. doi: 10.1210/jc.2010-1689. Epub 2010 Dec 8.
9
Identification of the first PAR1 deletion encompassing upstream SHOX enhancers in a family with idiopathic short stature.
Eur J Hum Genet. 2012 Jan;20(1):125-7. doi: 10.1038/ejhg.2011.210. Epub 2011 Nov 9.

引用本文的文献

2
Efficacy and Safety of Growth Hormone (GH) Therapy in Patients with SHOX Gene Variants.
Children (Basel). 2025 Mar 4;12(3):325. doi: 10.3390/children12030325.
3
GH Therapy in Non-Growth Hormone-Deficient Children.
Children (Basel). 2024 Dec 24;12(1):3. doi: 10.3390/children12010003.
4
Turner Syndrome and the Thyroid Function-A Systematic and Critical Review.
Int J Mol Sci. 2024 Dec 2;25(23):12937. doi: 10.3390/ijms252312937.
5
Turner Syndrome where are we?
Orphanet J Rare Dis. 2024 Aug 28;19(1):314. doi: 10.1186/s13023-024-03337-0.
7
Clinical practice guidelines for the care of girls and women with Turner syndrome.
Eur J Endocrinol. 2024 Jun 5;190(6):G53-G151. doi: 10.1093/ejendo/lvae050.
8
Efficacy and safety of GH treatment in Japanese children with short stature due to deficiency: a randomized phase 3 study.
Clin Pediatr Endocrinol. 2024;33(2):43-49. doi: 10.1297/cpe.2023-0070. Epub 2024 Jan 28.
9
The Use of Fluorescence Hybridisation in the Diagnosis of Hidden Mosaicism in Egyptian Patients with Turner Syndrome.
J Hum Reprod Sci. 2023 Oct-Dec;16(4):286-298. doi: 10.4103/jhrs.jhrs_128_23. Epub 2023 Dec 29.
10
Out of the Silence: Insights into How Genes Escape X-Chromosome Inactivation.
Epigenomes. 2023 Nov 23;7(4):29. doi: 10.3390/epigenomes7040029.

本文引用的文献

2
A Deletion of More than 800 kb Is the Most Recurrent Mutation in Chilean Patients with SHOX Gene Defects.
Horm Res Paediatr. 2015;84(4):254-7. doi: 10.1159/000439109. Epub 2015 Sep 3.
3
The growth response to GH treatment is greater in patients with SHOX enhancer deletions compared to SHOX defects.
Eur J Endocrinol. 2015 Nov;173(5):611-21. doi: 10.1530/EJE-15-0451. Epub 2015 Aug 11.
4
Heterozygous NPR2 Mutations Cause Disproportionate Short Stature, Similar to Léri-Weill Dyschondrosteosis.
J Clin Endocrinol Metab. 2015 Aug;100(8):E1133-42. doi: 10.1210/jc.2015-1612. Epub 2015 Jun 15.
5
Novel approaches to short stature therapy.
Best Pract Res Clin Endocrinol Metab. 2015 Jun;29(3):353-66. doi: 10.1016/j.beem.2015.01.003. Epub 2015 Feb 7.
7
Mice lacking the transcription factor SHOX2 display impaired cerebellar development and deficits in motor coordination.
Dev Biol. 2015 Mar 1;399(1):54-67. doi: 10.1016/j.ydbio.2014.12.013. Epub 2014 Dec 18.
9
Skeletal Deformity Associated with SHOX Deficiency.
Clin Pediatr Endocrinol. 2014 Jul;23(3):65-72. doi: 10.1297/cpe.23.65. Epub 2014 Aug 6.
10
Recombination in the human Pseudoautosomal region PAR1.
PLoS Genet. 2014 Jul 17;10(7):e1004503. doi: 10.1371/journal.pgen.1004503. eCollection 2014 Jul.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验